Evidence map›Paper›PMID 32539988›Full record

ArticleThe Lancet. Infectious diseases2020

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.

Sakiko Tabata, Kazuo Imai, Shuichi Kawano, Mayu Ikeda, Tatsuya Kodama, Kazuyasu Miyoshi, Hirofumi Obinata, Satoshi Mimura, Tsutomu Kodera, Manabu Kitagaki and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 19 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 19 syntheses or guidelines pooled it, 291 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Pooled it
  4. Systematic Review on Outbreaks of SARS-CoV-2 on Cruise, Navy and Cargo Ships.International journal of environmental research and public health · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.Clinica chimica acta; international journal of clinical chemistry · 2020
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Sakiko TabataSelf-Defense Forces Central Hospital, Tokyo, Japan.
Kazuo ImaiSelf-Defense Forces Central Hospital, Tokyo, Japan; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan. Electronic address: k_imai@saitama-med.ac.jp.
Shuichi KawanoSelf-Defense Forces Central Hospital, Tokyo, Japan; Japan Ground Self-Defense Force Medical Service School, Tokyo, Japan.
Mayu IkedaSelf-Defense Forces Central Hospital, Tokyo, Japan.
Tatsuya KodamaSelf-Defense Forces Central Hospital, Tokyo, Japan.
Kazuyasu MiyoshiSelf-Defense Forces Central Hospital, Tokyo, Japan.
Hirofumi ObinataSelf-Defense Forces Central Hospital, Tokyo, Japan; Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan.
Satoshi MimuraSelf-Defense Forces Central Hospital, Tokyo, Japan.
Tsutomu KoderaSelf-Defense Forces Central Hospital, Tokyo, Japan.
Manabu KitagakiSelf-Defense Forces Central Hospital, Tokyo, Japan.
Michiya SatoSelf-Defense Forces Central Hospital, Tokyo, Japan.
Satoshi SuzukiSelf-Defense Forces Central Hospital, Tokyo, Japan.
Toshimitsu ItoSelf-Defense Forces Central Hospital, Tokyo, Japan.
Yasuhide UwabeSelf-Defense Forces Central Hospital, Tokyo, Japan.
Kaku TamuraSelf-Defense Forces Central Hospital, Tokyo, Japan.
Self-Defense Forces Central Hospital · JPNippon Medical School · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ongoing COVID-19 pandemic is a global threat. Identification of markers for symptom onset and disease progression is a pressing issue. We described the clinical features of people infected on board the Diamond Princess cruise ship who were diagnosed with asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or mild or severe COVID-19, on admission to the Self-Defense Forces Central Hospital (Tokyo, Japan) and at the end of observation.

methodsThis retrospective, single-centre study included participants with laboratory-detected SARS-CoV-2 infection who were admitted to the Self-Defense Forces Central Hospital from Feb 11 to Feb 25, 2020. Clinical records, laboratory data, and radiological findings were analysed. Clinical outcomes were followed up until discharge or Feb 26, 2020, whichever came first. We defined asymptomatic infection as SARS-CoV-2 infection with no history of clinical signs and symptoms, severe COVID-19 as clinical symptoms of pneumonia (dyspnoea, tachypnoea, peripheral capillary oxygen saturation <93%, and need for oxygen therapy), and mild COVID-19 as all other symptoms. Clinical features on admission were compared among patients with different disease severity, including asymptomatic infection, at the end of observation. We used univariable analysis to identify factors associated with symptomatic illness among asymptomatic people infected with SARS-CoV-2 and disease progression in patients with COVID-19.

findingsAmong the 104 participants included in the final analysis, the median age was 68 years (IQR 47-75) and 54 (52%) were male. On admission, 43 (41%) participants were classified as asymptomatic, 41 (39%) as having mild COVID-10, and 20 (19%) as having severe COVID-19. At the end of observation, 33 (32%) participants were confirmed as being asymptomatic, 43 (41%) as having mild COVID-19, and 28 (27%) as having severe COVID-19. Serum lactate hydrogenase concentrations were significantly higher in the ten participants who were asymptomatic on admission but developed symptomatic COVID-19 compared with the 33 participants who remained asymptomatic throughout the observation period (five [50%] vs four [12%] participants; odds ratio 7·25, 95% CI 1·43-36·70; p=0·020). Compared with patients with mild disease at the end of observation, patients with severe COVID-19 were older (median age 73 years [IQR 55-77] vs 60 years [40-71]; p=0·028) and had more frequent consolidation on chest CT (13 [46%] of 28 vs nine [21%] of 43; p=0·035) and lymphopenia (16 [57%] vs ten [23%]; p=0·0055) on admission.

interpretationOlder age, consolidation on chest CT images, and lymphopenia might be risk factors for disease progression of COVID-19 and contribute to improved clinical management.

fundingNone.

Indexed as

PandemicsAdultAgedBetacoronavirusCoronavirus InfectionsCOVID-19Disease ProgressionFemaleHospitalsHumansJapanLungLymphopeniaMaleMiddle AgedPneumonia, Viral

Identifiers

PMID32539988
PMCPMC7292609
OpenAlexW3034523319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.